- News Releases
"I think we've accomplished in this year what normally would take seven years," says Saad Kenderian, M.B., Ch.B., a Mayo Clinic cancer researcher.
Claudia Lucchinetti, M.D., director of Mayo Clinic's Center for Clinical and Translational Science, says "it wouldn't have happened just about anywhere else but at Mayo Clinic."
Dr. Kenderian and Dr. Lucchinetti are talking about the way the science, people and resources came together during the COVID-19 pandemic, to repurpose an experimental therapy, called lenzilumab, for patients with COVID-19 pneumonia, and from there, to a phase 3 clinical trial — all in about one year.
Jenny Weis, research administrator for the Center for Clinical and Translational Science, agrees.
"We assembled the A-Team," Weis says. "We took what we were already experts at and we held hands and we sprinted."
The lenzilumab translational science effort was carried out by a multidisciplinary team including Andrew Badley, M.D.; Adil Bharucha, M.D.; Charles Burger, M.D.; Tamara Evans; Andrea Kukla; Saad Kenderian M.B., Ch.B; Claudia Libertin, M.D.; Claudia Lucchinetti, M.D.; Robert Orenstein, M.D.; Mindy Shea; Zelalem Temsgen, M.D.; Holly Tuseth; Jenny Weis; R. Scott Wright, M.D., and collaborators from academic medical centers and industry.
Stepping on the gas for COVID-19 and lenzilumab
At the beginning of the pandemic, experimental therapies were the only options available to help patients. To turn those therapies into standard care required clinical and translational research. Research leaders turned to experts in the Mayo Clinic Center for Clinical and Translational Science to help streamline the institution’s COVID-19 research strategy.
“We knew that in order to do our best work and to have the greatest impact for patients, we needed a union of forces. We had to organize ourselves, prioritize and move together as one," says Andrew Badley, M.D., chair of the Mayo Clinic SARS-CoV-2 COVID-19 Research Task Force, a group charged with oversight of all COVID-19-related research activities.
This multidisciplinary group aligns research projects and resources across the institution. They rigorously review every COVID-19 research proposal, approving only those posing the best questions or with the highest likelihood of helping patients. When the task force sees a COVID-19 research idea with potential, they give it the green light and a dedicated team of experts from CCaTS to help activate the study and keep it moving forward.
Read the rest of the article on Discovery's Edge.
Other Mayo Clinic medical research websites:
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.
For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
Learn more about tracking COVID-19 and COVID-19 trends.
To simplify COVID-19 vaccine administration, the Food and Drug Administration ended the use of the original monovalent COVID-19 vaccines on April 18. People who are due for the bivalent vaccine ...
Like many people throughout the world, Matthew Binnicker, Ph.D., remembers exactly where he was and what he was doing when COVID-19 was classified as a pandemic. ...
While COVID-19 rates in the U.S. are relatively low and are declining, the World Health Organization (WHO) is keeping an eye on a new COVID-19 ...